Literature DB >> 7754805

Rheumatoid arthritis and bone mineral density in elderly women. The Study of Osteoporotic Fractures Research Group.

N E Lane1, A R Pressman, V L Star, S R Cummings, M C Nevitt.   

Abstract

Previous studies have suggested that women with rheumatoid arthritis (RA) have decreased bone mineral density (BMD) in both the appendicular and axial skeleton. The purpose of this investigation was to determine the association of RA and BMD from a community-based sample of ambulatory Caucasian women age 65 and over. BMD was measured by dual-energy X-ray absorptiometry (DXA) at the hip and lumbar spine and by single photon absorptiometry (SPA) at the distal radius and calcaneus. Study subjects included 120 postmenopausal women with RA who were further classified according to corticosteroid use, i.e., never users, current users, and ex-users, and 7966 age-similar controls. Elderly women with RA had a lower age-adjusted bone density of the distal radius, calcaneus, hip, and lumbar spine. Women with RA who were current users of steroids had the lowest BMD at both appendicular sites and at the hip, but those who never used steroids also had a significantly decreased BMD at all sites. The BMD of women with RA who had never used steroids remained significantly decreased at the distal radius, calcaneus, and hip after adjustment for age, BMD determinants, and functional outcomes of RA. Functional outcomes of RA largely accounted for the lower BMD of women who were currently using steroids. Women with RA have lower appendicular and axial bone mass that is not attributable to the use of steroids. Those currently taking steroids have even lower appendicular and axial bone mass that may reflect their poorer functional outcome and is likely to increase the risk of fractures.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7754805     DOI: 10.1002/jbmr.5650100212

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  23 in total

Review 1.  Skeletal complications of rheumatoid arthritis.

Authors:  L Heinlen; M B Humphrey
Journal:  Osteoporos Int       Date:  2017-08-04       Impact factor: 4.507

2.  Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study.

Authors:  Seo Young Kim; Sebastian Schneeweiss; Jun Liu; Daniel H Solomon
Journal:  J Bone Miner Res       Date:  2012-04       Impact factor: 6.741

3.  Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage.

Authors:  Mona Helmy Abdel Meguid; Yousry Hasan Hamad; Rania Shafek Swilam; Mohamed Samy Barakat
Journal:  Rheumatol Int       Date:  2012-04-25       Impact factor: 2.631

Review 4.  The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis.

Authors:  C J Edwards; E Williams
Journal:  Osteoporos Int       Date:  2010-03-13       Impact factor: 4.507

5.  Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis.

Authors:  M Vis; E A Havaardsholm; G Haugeberg; T Uhlig; A E Voskuyl; R J van de Stadt; B A C Dijkmans; A D Woolf; T K Kvien; W F Lems
Journal:  Ann Rheum Dis       Date:  2006-04-10       Impact factor: 19.103

6.  The limited effects of anti-tumor necrosis factor blockade on bone health in patients with rheumatoid arthritis under the use of glucocorticoid.

Authors:  Tadashi Okano; Tatsuya Koike; Masahiro Tada; Yuko Sugioka; Kenji Mamoto; Shigeyuki Wakitani; Hiroaki Nakamura
Journal:  J Bone Miner Metab       Date:  2014-09       Impact factor: 2.626

7.  Bone mineral density in patients with early rheumatoid arthritis treated with corticosteroids.

Authors:  George S Habib; Shehadeh Haj
Journal:  Clin Rheumatol       Date:  2004-09-14       Impact factor: 2.980

8.  Significance of risk factors for osteoporosis is dependent on gender and menopause in rheumatoid arthritis.

Authors:  Peter Oelzner; Antje Schwabe; Gabriele Lehmann; Thorsten Eidner; Sybille Franke; Gunter Wolf; Gert Hein
Journal:  Rheumatol Int       Date:  2008-04-30       Impact factor: 2.631

9.  Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis.

Authors:  Kageyama Yasunori; Takahashi Masaaki; Nagafusa Tetsuyuki; Kobayashi Hayato; Nagano Akira
Journal:  Clin Rheumatol       Date:  2008-03-13       Impact factor: 2.980

Review 10.  Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases.

Authors:  Sherine E Gabriel; Kaleb Michaud
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.